A Phase 1 interventional study of Bictegravir in HIV, sponsored by Gilead Sciences. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-11.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral bictegravir (formerly GS-9883) in adults with impaired renal function relative to matched, healthy controls with normal renal function. Each participant in the renal impairment groups will be matched for age (± 10 years), gender, and body mass index [BMI (± 20%, 18 ≤ BMI ≤ 40 kg/m\^2)] with a participant in the control group.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
All Individuals:
Individuals with impaired renal function
Chronic stable renal impairment without recent clinical change
Healthy individuals
Key Exclusion Criteria:
All Individuals:
Individuals with impaired renal function
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
Drug: Bictegravir
Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
Drug: Bictegravir
Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
Drug: Bictegravir
75 mg tablet administered orally
Also known as: GS-9883
Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)
AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
PK Parameter: AUCinf of Bictegravir (Free)
Free AUCinf was calculated based on unbound plasma bictegravir (AUCinf × percentage unbound bictegravir ÷ 100 for each participant).
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
PK Parameter: AUClast of Bictegravir (Total)
AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
PK Parameter: AUClast of Bictegravir (Free)
Free AUClast was calculated based on unbound plasma bictegravir (AUClast × percentage unbound bictegravir ÷ 100 for each participant).
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
PK Parameter: Cmax of Bictegravir (Total)
Cmax is defined as the maximum observed plasma concentration of drug.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
PK Parameter: Cmax of Bictegravir (Free)
Free Cmax was calculated based on unbound plasma bictegravir (Cmax × percentage unbound bictegravir ÷ 100 for each participant).
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) are defined as any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
Time frame: First dose date to Day 31
Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities
A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment and occurring after the predose visit and on or before the date of the administration of study drug plus 30 days. The most severe graded abnormality from all tests was counted for each participant. Toxicity grade was defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening.
Time frame: First dose date to Day 31
Participants were enrolled at study sites in the United States and New Zealand. The first participant was screened on 17 April 2015. The last study visit occurred on 13 July 2015.
| Milestone | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| Started | 11 | 8 |
| Completed | 10 | 8 |
| Not completed | 1 | 0 |
| Withdrew: Enrolled and never dosed | 1 | 0 |
AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.
| h*ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) | 138169.7 ± 61291.27 | 170105.6 ± 42213.18 |
Free AUCinf was calculated based on unbound plasma bictegravir (AUCinf × percentage unbound bictegravir ÷ 100 for each participant).
| h*ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| PK Parameter: AUCinf of Bictegravir (Free) | 830.6 ± 266.59 | 824.5 ± 203.49 |
AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.
| h*ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| PK Parameter: AUClast of Bictegravir (Total) | 136956.4 ± 60557.34 | 168876.8 ± 41706.37 |
Free AUClast was calculated based on unbound plasma bictegravir (AUClast × percentage unbound bictegravir ÷ 100 for each participant).
| h*ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| PK Parameter: AUClast of Bictegravir (Free) | 822.5 ± 263.22 | 818.6 ± 201.18 |
Cmax is defined as the maximum observed plasma concentration of drug.
| ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| PK Parameter: Cmax of Bictegravir (Total) | 5977.0 ± 2079.57 | 7227.5 ± 2135.56 |
Free Cmax was calculated based on unbound plasma bictegravir (Cmax × percentage unbound bictegravir ÷ 100 for each participant).
| ng/mL | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| PK Parameter: Cmax of Bictegravir (Free) | 37.7 ± 8.15 | 35.0 ± 9.94 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | 20.0 | 25.0 |
A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment and occurring after the predose visit and on or before the date of the administration of study drug plus 30 days. The most severe graded abnormality from all tests was counted for each participant. Toxicity grade was defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening.
| percentage of participants | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| Grade 1 | 20.0 | 25.0 |
| Grade 2 | 40.0 | 25.0 |
| Grade 3 | 40.0 | 0 |
| Grade 4 | 0 | 0 |
Collected over First dose date to Day 31. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Severe Renal Impairment | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Normal Renal Function | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Severe Renal Impairment | Normal Renal Function |
|---|---|---|
| ConstipationGastrointestinal disorders | 0/10 | 1/8 |
| HeadacheNervous system disorders | 0/10 | 1/8 |
| NauseaGastrointestinal disorders | 1/10 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 1/10 | 0/8 |
| EcchymosisSkin and subcutaneous tissue disorders | 1/10 | 0/8 |
The Safety Analysis Set included participants who received the single dose of bictegravir.
| Age, Continuous(years) | Severe Renal Impairment | Normal Renal Function | Total |
|---|---|---|---|
| Mean | 62 ± 15.6 | 56 ± 14.7 | 59 ± 15.1 |
| Sex: Female, Male(Participants) | Severe Renal Impairment | Normal Renal Function | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 7 | 6 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Severe Renal Impairment | Normal Renal Function | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 7 | 6 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Severe Renal Impairment | Normal Renal Function | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 7 | 7 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from Apr 2015 to primary completion in Jul 2015, 2 months.
Results were first posted in Oct 2019, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bictegravir